Brigo, Francesco http://orcid.org/0000-0003-0928-1577
Lattanzi, Simona
Nardone, Raffaele
Trinka, Eugen
Article History
First Online: 24 July 2019
Compliance with Ethical Standards
:
: No funding was received for the conduct of this study or the preparation of this article.
: Francesco Brigo has acted as a paid consultant to Eisai and LivaNova, and received travel support from Eisai. Eugen Trinka has acted as a paid consultant to Eisai, EVER Neuro Pharma, Biogen Idec, Medtronics, Bial, and UCB and has received speakers’ honoraria from Bial, Eisai, Boehringer Ingelheim, Biogen, Newbridge, Novartis, and UCB Pharma in the past 3 years. Eugen Trinka has received research funding from UCB Pharma, Biogen, Novartis, Bayer, Eisai, Red Bull, Merck, the European Union, FWF Österreichischer Fond zur Wissenschaftsförderung, and Bundesministerium für Wissenschaft und Forschung. Eugen Trinka is also part of the investigators planning the ESET Trial and a member of the Task Force on Classification of Status Epilepticus of the International League Against Epilepsy. Simona Lattanzi and Raffaele Nardone have no conflicts of interest that are directly relevant to the content of this article.
: This is a systematic review of the literature, and not an original research study involving human participants and/or animals.